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A B S T R A C T
The coordination of biologically active moieties to the axial positions of Pt(IV) derivatives of Pt(II) anticancer
drugs allows the co-delivery and simultaneous activation of two pro-drugs for combination therapy. Pt(IV)
complexes with a redox modulator as an axial ligand can kill cancer cells by a mechanism combining DNA
platination and generation of oxidative stress. In this study we evaluated the cytotoxicity of Pt(IV) complexes
based on the oxaliplatin scaffold and the pro-oxidant indole-3-propionate in cisplatin-sensitive and cisplatin-
resistant ovarian cancer cells. A series of five complexes was synthesized and characterized by 1H and 195Pt NMR
spectroscopy, IR spectroscopy, mass spectrometry and elemental analysis; trans-[Pt(DACH)(ox)(IPA)(OH)] (1),
trans-[Pt(DACH)(ox)(IPA)2] (2), trans-[Pt(DACH)(ox)(IPA)(bz)] (3), trans-[Pt(DACH)(ox)(IPA)(suc)] (4), and
trans-[Pt(DACH)(ox)(IPA)(ac)] (5) (DACH = 1,2-diaminocyclohexane (1R,2R)-(−), ox = oxalate, IPA = indole-
3-propionate, bz = benzoate, suc = succinate and ac = acetate). The complexes were shown to produce cellular
reactive oxygen species (ROS) in a time-dependent manner. The most potent ROS producer, complex 1, also
elicited the highest cytotoxicity. Complex 1 was shown to form the mono- and bis-adducts [Pt(DACH)(guano-
sine)(OH)]+ and [Pt(DACH)(guanosine)2]2+ in the presence of ascorbic acid, suggesting that on activation the
released oxaliplatin will interact with DNA.
1. Introduction
About 50% of cancer patients who undergo chemotherapy receive
one of the three worldwide approved platinum(II) complexes, cisplatin,
carboplatin and oxaliplatin, either alone or in combination with other
anticancer drugs [1]. Co-administration of two or more chemother-
apeutics with independent modes of action is widely used to reduce the
risk of resistance development and to enhance the anticancer efficacy
through synergistic effects [2]. However, different selectivities and
pharmacokinetics of the individual drugs can pose significant chal-
lenges in the application of combination therapy regimens. Oxidation of
Pt(II) to Pt(IV) allows the covalent attachment of a second biologically
active entity to the axial positions of the cisplatin-, carboplatin- or
oxaliplatin-scaffold [3–20]. In addition to the simultaneous delivery of
the Pt drug and the co-administered drug, Pt(IV) complexes have the
advantages of a higher stability, lower toxicity, reduced side effects and
potential for oral administration [3,4]. Dual-action Pt(IV) compounds
are pro-drugs that require activation by intracellular reducing agents to
release the active Pt(II) species and the axial ligands (Chart 1) [3,21].
We have recently reported that the coordination of indole car-
boxylic acids to the axial positions of the Pt(IV) derivative of cisplatin
leads to potent anticancer agents that overcome cisplatin resistance
[22]. Indole carboxylic acids are redox modulators that can act as pro-
oxidants [23–27]. Indole acetic acid, for example, is used in the oxi-
dation therapy of cancer [23]. We showed that the Pt(IV) indole-3-
propionic acid complexes cis,cis,trans-[Pt(NH3)2Cl2(IPA)(OH)], cis,cis,-
trans-[Pt(NH3)2Cl2(IPA)2], cis,cis,trans-[Pt(NH3)2Cl2(IPA)(Bz)] and
cis,cis,trans-[Pt(NH3)2Cl2(IPA)(Ac)] (IPA = indole-3-propionate, Bz =
benzoate, Ac = acetate) exert their cytotoxic activity by a dual-action
mechanism combining DNA platination and the generation of reactive
oxygen species (ROS). cis,cis,trans-[Pt(NH3)2Cl2(IPA)(OH)] was found
to be up to four times more effective than cisplatin [22].
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Oxaliplatin (Chart 1) is a third-generation Pt(II) drug that is ap-
proved for the treatment of metastatic colorectal cancer and is also
active against lung and ovarian cancer cell lines [28,29]. It contains a
more stable leaving group compared to cisplatin and the R,R-diami-
nocyclohexane (DACH) chelating ligand [30]. The latter leads to a
spectrum of activity that is different from that of cisplatin and carbo-
platin. Oxaliplatin also shows a different resistance profile and is
usually better tolerated than cisplatin [31,32]. In continuation of our
previous work we therefore synthesized the oxaliplatin analogues of the
cis,cis,trans-[Pt(NH3)2Cl2(IPA)Y] complexes and investigated their cy-
totoxicity and ROS generating capability in cisplatin-sensitive and cis-
platin-resistant ovarian cancer cells.
2. Results and discussion
The five complexes based on oxaliplatin (Chart 2) were synthesised
as shown in Scheme 1 and in the Experimental Section in the
Supporting Information. Briefly, oxaliplatin was oxidised to the corre-
sponding di-hydroxido Pt(IV) complex (A) by H2O2 in aqueous solution
(Scheme 1). A was reacted with the activated N-hydroxysuccinimide
(NHS) ester of indole-3-propionic acid (B) in DMSO solution to obtain
complex 1. This complex was the precursor to obtain complexes 3–5
that could be isolated by precipitation with diethyl ether from a DMF
solution containing 1 and the corresponding anhydride; benzoic (3),
succinic (4) and acetic (5) anhydride, respectively. 2 was obtained by
reaction of A with a large excess of B in DMSO.
The complexes were characterized by 1H and 195Pt NMR spectro-
scopy, infra-red spectroscopy, elemental analysis and mass spectro-
metry (Supporting Information, Figures 1S –12S). The purity and the
stability of the complexes for 36 h have been evaluated in HEPES buffer
solution by HPLC (Fig. 13S). Elemental analyses are in good agreement
with the expected values for the complexes. In the ESI-MS spectra the
[M−H]− or [M+Cl]− parent ions of the platinum(IV) complexes were
readily observed with the typical isotope pattern of Pt. The IR spectra
displayed characteristic C]O stretching vibrations around 1710 cm−1
and 1650 cm−1 for all the complexes while the symmetric and anti-
symmetric NeH stretching bands of the amine ligands were found be-
tween 3325 and 3400 cm−1 and between 3150 and 3190 cm−1. The
proton resonances of the coordinated amine ligands in the 1H NMR
spectrum of 1 appear as multiplet at ca. 7.08–8.52-ppm. This multiplet
is broadened and downfield shifted to ca. 8.12–8.55 ppm in complexes
2–5. The chemical shift values of the amine protons are well in line with
those of previously reported Pt(IV) complexes based on oxaliplatin
[33,34]. The 195Pt NMR spectrum of 1 in DMF (insert D2O) shows a
single resonance at 1389 ppm that is shifted downfield to ca. 1590 ppm
in the di-carboxylato complexes 2–5. The presence of an additional
electron withdrawing carboxylate ligand in 2–5 causes a de-shielding
effect of about 200 ppm on the platinum signal with respect to the
mono-carboxylated complex 1.
The anticancer activities of the complexes were evaluated in two
human ovarian carcinoma cells lines, cisplatin-sensitive A2780 and
cisplatin-resistant A2780cis. The cytotoxicity was determined after in-
cubation for 24 and 48 h using the colorimetric MTT assay and IC50
values are reported in Table 1. For comparison purposes, the cyto-
toxicities of cisplatin, oxaliplatin and of the free IPA ligand were as-
sessed under the same experimental conditions. The complexes are less
active than cisplatin, in particular in the sensitive A2780 cell line,
whereas they show higher activity than the reference drug oxaliplatin.
The IC50 values of 1–5 in the A2780 cells are about 3 to 6 times lower at
the 48 h timepoint than at the 24 h timepoint. The decrease in the IC50
value with prolonged exposure time is less pronounced for cisplatin.
That is, the oxaliplatin derivatives take longer to exert their cytotoxic
effects. After 48 h, the activity of 1 is comparable to that of cisplatin
(IC50(48 h) = 12.6 (1) vs. 10.5 (cisplatin)). The complexes show cross-
resistance with cisplatin.
In the A2780 cell line the most active complex at the 48 h timepoint
is the mono-carboxylated complex 1 with one axial OH group. The bis-
substituted complex 2 with two indole acids in both the axial positions
Chart 1. The three FDA-approved Pt(II) anticancer drugs, general structure of
Pt(IV) pro-drugs for cisplatin and pro-drug activation by reduction.
Chart 2. Structures of complexes 1–5.
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is slightly more active in the resistant cells (48 h timepoint). The finding
that the mono- and the bis-PBA complex exert the strongest cytotoxic
activity is in line with the cytotoxicity data observed for the analogous
cisplatin-based complexes [22].
The generally not exceptional activity of these complexes may be
ascribed to the reduction rate of these complexes under physiological
conditions. As mentioned in the introduction, Pt(IV) complexes are pro-
drugs and must be reduced to active Pt(II) agents. The reduction of 1
was studied via HPLC in the presence of an excess of ascorbic acid in
HEPES buffer at pH 7 and 37 °C. As shown in Fig. 1, the complex re-
leases the axial IPA ligand and is reduced to the active oxaliplatin(II)
species. However, the reduction kinetics are much slower compared to
the analogous Pt(IV) compound based on cisplatin [22]. After 72 h
there is still 19% of the starting Pt(IV) complex 1. Under the same
conditions, cis,cis,trans-[Pt(NH3)2Cl2(IPA)(OH)] was completely re-
duced within 24 h [22]. A lower reduction rate corresponds to a lower
cytotoxicity because the active oxaliplatin is not completely released. In
general, a low cytotoxic activity can also be due to a low lipophilicity
and poor cellular uptake. However, we did not further investigate this
possibility, as for the analogous cisplatin derivatives no correlation
between lipophilicity, cellular uptake and IC50 value was observed. The
slow pro-drug activation is consistent with the delayed cytotoxicity of 1
whose IC50 value becomes comparable to that of cisplatin at the 48 h
timepoint.
To further confirm the activation mechanism, 1 was incubated with
guanosine (G) in the presence of sodium ascorbate to simulate the in-
teraction of the platinum drug with the nucleobases of DNA. The mass
spectrum of the reaction mixture (Fig. 2) clearly shows the presence of
two peaks, corresponding to the species [Pt(DACH)(G)2]2+ (m/z
875.25; {M−H}+) and [Pt(DACH)(OH)(G)]+ (m/z 609.16) which
suggests that 1 can bind to the guanosine residues of DNA upon re-
duction. (Chart S1). The peak observed at m/z= 742.22 can be as-
signed to [Pt(DACH)(guanosine)(guanine)-H]+ resulting from the loss
of the sugar entity of one guanosine ligand. It is worthy of note that the
incubation of 1 with guanosine without the reducing agent ascorbic
acid does not give any Pt-guanosine adducts.
Indole carboxylic acids are agents that can alter and modify the
cellular redox state and the cisplatin analogues of 1–5 induced a sig-
nificant increase in ROS production. We speculated that the oxaliplatin-
based Pt(IV) complexes with axial indole propionate ligands could also
generate cellular oxidative stress. The generation of ROS in A2780 and
A2780cis cells after incubation with 1–5, cisplatin, oxaliplatin and IPA
was measured. ROS levels were monitored over a 2 h period using 2′,7′-
dichlorofluorescein diacetate (H2DCFDA) as a peroxide-sensitive
Scheme 1. Syntheses of complexes 1–5.
Table 1
IC50 values of the Pt(IV) complexes 1–5, cisplatin, oxaliplatin and the free li-
gand IPA in A2780 and A2780cis cells determined by the MTT test.
Complex IC50 (µM) ± S.D.
A2780 A2780cis
24 h 48 h 24 h 48 h
1 74.40 ± 8.1 12.62 ± 0.02 66.91 ± 1.8 55.68 ± 1.7
2 53.32 ± 1.8 15.47 ± 1.72 70.48 ± 1.83 46.17 ± 1.61
3 54.52 ± 1.7 16.10 ± 1.8 55.26 ± 2.30 54.59 ± 2.5
4 58.39 ± 8.7 16.55 ± 8.5 132.52 ± 2.7 63.69 ± 7.4
5 70.10 ± 4.65 21.45 ± 2.7 103.01 ± 6.1 47.56 ± 0.68
Cisplatin 20.10 ± 4.65 10.46 ± 2.1 60.80 ± 8.2 29.04 ± 6.7
Oxaliplatin 83.25 ± 5.7 19.80 ± 1.10 110.68 ± 16.8 86.37 ± 2.9
IPA > 200 > 200 > 200 > 200
D. Tolan, et al. Inorganica Chimica Acta 492 (2019) 262–267
264
fluorescent dye and the results are reported in Fig. 3 and Fig. 14S in the
Supporting Information. All the complexes were able to stimulate the
production of ROS in a time-dependent manner and the increased
oxidative stress follows the order 1 > 4 > 3 > 2 > 5. Complex 1 is
the most efficient ROS generator and is significantly more potent than
the free IPA ligand and the reference drugs cisplatin and oxaliplatin.
The higher cytotoxic activity of complex 1 with respect to the other
complexes is probably due to a synergistic effect of the two active
species released upon intracellular reduction, oxaliplatin and IPA. As
known, while oxaliplatin will interact with DNA as its cellular target,
IPA will increase the ROS production with these two mechanisms op-
erating simultaneously.
3. Conclusions
The most active complex of the newly synthesized Pt(IV) derivatives
of oxaliplatin, cis,cis,trans-[Pt(DACH)(ox)(IPA)(OH)] is more potent
than oxaliplatin in A2780 ovarian cancer cells. Overall, compared to
their cisplatin-based counterparts reported earlier by us [22], 1–5 are
only moderately cytotoxic. This is in line with reports on other ox-
aliplatin/cisplatin pro-drugs [17] and can be attributed to the relatively
slow reduction kinetics of Pt(IV) derivatives of oxaliplatin. 1–5 are
more efficient ROS producers in A2780 and A2780cis cells than the free
indole carboxylic acid.
Fig. 1. HPLC analysis of the reaction of 1 with ascorbic acid at 37 °C and pH 7 at different times. *= ascorbic acid.
Fig. 2. ESI-MS spectrum of the reaction between 1 and guanosine in presence of sodium ascorbate.
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